

August 3, 2006

Dainippon Sumitomo Pharma Co., Ltd.  
Torii Pharmaceutical Co., Ltd.

**Conclusion of an Agreement over Co-promotion of Dops<sup>®</sup> for the Treatment of Orthostatic Hypotension**

Dainippon Sumitomo Pharma Co., Ltd. (Head Office: Osaka City, President: Kenjiro Miyatake; hereinafter called “DSP”) and Torii Pharmaceutical Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Norihiko Matsuo; hereinafter called “Torii”) announced today that the companies concluded a contract over co-promotion of Dops<sup>®</sup> (generic name: droxidopa) in the Japanese hemodialysis market. Dops<sup>®</sup> is a norepinephrine-induced adrenergic neurofunction improving agent developed by DSP and currently distributed in Japan by DSP.

Following this agreement, DSP and Torii will begin co-promotion of Dops<sup>®</sup> in the Japanese hemodialysis market in October 2006.

Dops<sup>®</sup>, a precursor of norepinephrine (NE), is converted to NE thereby improving symptoms related to NE deficiency. Dops<sup>®</sup> initially received approval in 1989 for the treatment of frozen gait or dizziness associated with Parkinson’s Disease and others in Japan. In 2000, DSP received expanded marketing approval to include treatment of vertigo, dizziness and weakness associated with orthostatic hypotension in hemodialysis patients.

Our decision to begin co-promotion of this product is based on DSP’s desire to increase the sales of Dops<sup>®</sup> and Torii’s intention to expand its lineup of products for the hemodialysis market. DSP and Torii believe that co-promotion of Dops<sup>®</sup> in the hemodialysis market will contribute to improving the ADL (activities of daily living) and QOL (quality of life) of hemodialysis patients.